API Holdings, the parent company of PharmEasy backed by global private equity firm TPG, has successfully repaid its outstanding term debt of ₹1,050 crore using proceeds from a partial stake sale in Thyrocare and internal accruals. According to reports from Moneycontrol, the company retained a 51.02 percent controlling stake in the listed diagnostics company while completing this debt repayment. Managing Director and CEO Rahul Guha stated that the company achieved debt-free status much earlier than anticipated and is now well positioned for profitability milestones. The company counts TPG, Prosus Ventures, Temasek, Ranjan Pai's Manipal Education and Medical Group (MEMG), CDPQ, LGT Lightrock, Eight Roads and Think Investments among its financial investors.
API Holdings is targeting profitability in its core business excluding Thyrocare by September 2027, with consolidated profitability already achieved. As reported by Moneycontrol, all operating businesses including PharmEasy, Ascent and Aknamed are already EBITDA positive before allocation of central costs. The remaining drag comes primarily from head-office expenses including technology, finance, human resources, legal and professional costs. Excluding Thyrocare, EBITDA losses have narrowed significantly from ₹637 crore in FY24 to ₹396 crore in FY25 and ₹168 crore in FY26, with further improvement expected this year before reaching break-even by Q2FY28. Operating expenses have fallen from ₹1,225 crore in FY24 to ₹943 crore in FY26.
Both an independent IPO of API Holdings and a potential merger with Thyrocare remain under consideration, but Guha emphasized that the company will decide only after achieving its profitability target. According to Moneycontrol reports, Guha stated that all options remain open once the profitability milestone is crossed, including a merger with Thyrocare or an IPO, but the immediate focus remains on profitability. The company has not raised equity since 2021 and plans to grow revenue at around 15 percent annually using internal accruals and bank-funded working capital, with further fundraising only considered once the company decides between IPO and merger options. Guha emphasized that the company will not rush an IPO merely to take advantage of favorable market conditions, stating that his mission is to take a great company to IPO once it becomes profitable.
The turnaround strategy involves significant operational improvements, with operating expenses falling from ₹1,225 crore in FY24 to ₹943 crore in FY26. As reported by Moneycontrol, PharmEasy now procures almost entirely through the group's own distribution operations, while common warehousing, procurement and finance functions are helping reduce costs. Higher-margin products and services already contribute around 25 percent of PharmEasy's revenue, while generics and private-label products account for about 9 percent. Guha emphasized that the company is no longer a medicine delivery platform but an integrated outpatient healthcare platform, positioning it to benefit from its asset-light structure as revenue grows. The company does not intend to immediately tap investors for fresh growth capital, with Guha preferring to grow at a modest pace using internal accruals rather than major fundraising.
